THIS WEBSITE IS INTENDED FOR U.S. RESIDENTS ONLY |For Patients

OFFER PATIENTS A CHOICE IN BOWEL PREPARATION

SUTAB and SUFLAVE have not been compared in head-to-head studies.
Data presented below are from independent clinical trials.

ASGE/ACG Task Force on Quality Indicators targets
≥90% bowel prep adequacy with a 1C recommendation¹

Most patients may qualify for savings.

SEE TERMS AND CONDITIONS

THE TABLET CHOICE

Tablets and packaging not shown actual size.

RESULTS FROM A PHASE 3
CLINICAL TRIAL

92%

of patients in two pivotal trials achieved successful
bowel cleansing with SUTAB^2,3*

97%

of patients achieved prep adequacy with SUTAB³

91%

of patients in one pivotal trial rated SUTAB as tolerable
to very easy to consume^2†

52% of all SUTAB and MoviPrep^® patients reported
at least one selected gastrointestinal adverse reaction^2,3‡
More SUTAB patients reported experiencing nausea
and vomiting than competitor, with ≤1% of these
reports considered severe^2‡

78%

of patients in one pivotal trial would request SUTAB
again for a future colonoscopy^3†

Study Design³: Study 1 was a phase 3 trial that was conducted in 22 US sites. Of the 620 subjects who enrolled, 548 patients were evaluable for efficacy analyses. The primary endpoint was the percentage of subjects with successful cleansing, which was based on the US FDA Bowel Prep Scoring Scale, the goal of which was to determine non-inferiority against MoviPrep. Secondary endpoints included prep adequacy, cecal intubation and adenoma detection rates, procedure duration, and intraprocedural water. Safety follow-up visits were required 24-48 hours after colonoscopy and on days 7 and 30 if adverse events or lab abnormalities were indicated. A subset of colonoscopies was graded by central readers (exploratory). The primary endpoint of non-inferiority was met.

Success was the primary endpoint and was defined in non-inferiority trials as an overall cleansing assessment of 3 (good) or 4 (excellent) by the blinded endoscopist; scores were assigned following completion of the colonoscopy.

^†

Patients completed a preference questionnaire following completion of study drug to capture their perceptions of the preparation experience. This questionnaire has not undergone formal validation.

^‡

Patients were queried for selected gastrointestinal adverse reactions of upper abdominal pain, abdominal distension, nausea, and vomiting following completion of study drug, rating the intensity as mild, moderate, or severe.^2,3

MoviPrep is a registered trademark of Velinor AG.

View the Full Prescribing Information and Medication Guide.

Visit SUTAB.com

Most patients may qualify for savings.

SEE TERMS AND CONDITIONS

THE FLAVOR CHOICE

Packaging not shown actual size.

RESULTS FROM A PHASE 3
CLINICAL TRIAL

94%

of patients achieved successful* bowel cleansing
with SUFLAVE^4,5

99%

of patients achieved prep adequacy with SUFLAVE⁵

87%

of patients found SUFLAVE tolerable to very easy
to consume⁵

79%

of patients found SUFLAVE neutral to very pleasant⁵

THE MAJORITY OF PATIENTS SAID SUFLAVE
TASTES LIKE A SPORTS DRINK⁵ Suflave Lemon

Study Design^4,5: This phase 3 trial was conducted in multiple sites. Of the 500 subjects who enrolled, 450 were evaluable for efficacy analyses. The primary endpoint was the percentage of subjects with successful cleansing, which was defined as a rating of excellent or good as assigned by the local endoscopist utilizing the US FDA Bowel Prep Scoring Scale. Secondary endpoints included prep adequacy, cecal intubation and adenoma detection rates, procedure duration, and intraprocedural water. Independent central readers also reviewed all colonoscopy videos and provided a global cleansing grade, as well as segmental grades, on insertion and withdrawal using a 4-point scale of excellent, good, fair, and poor. The goal of the study was to establish non-inferiority of SUFLAVE to SUPREP Bowel Prep Kit, using a 10% non-inferiority margin.

Success was defined as an overall cleansing assessment of excellent or good by the blinded endoscopist; scores were assigned following completion of the colonoscopy; P<0.001 in this non-inferiority trial.

The American Society for Gastrointestinal Endoscopy (ASGE)/American College of Gastroenterology (ACG) Task Force on Quality in Endoscopy is a group of expert endoscopists selected by the ASGE and ACG to review all available data on quality measurements for endoscopic procedures. Their goal is to ensure that patients receive the correct procedure and diagnosis, that therapy is properly performed, and that all this is accomplished with minimum risk. Visit https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3104386/ to learn more.

SUFLAVE^™ has a lemon-lime flavor.⁴

View the Full Prescribing Information and Medication Guide.

IMPORTANT SAFETY INFORMATION

SUTAB IMPORTANT SAFETY INFORMATION

INDICATION
SUTAB^® (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

CONTRAINDICATIONS
Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to any ingredient in SUTAB.

DOSAGE AND ADMINISTRATION
A low residue breakfast may be consumed. After breakfast, only clear liquids may be consumed until after the colonoscopy. Administration of two doses of SUTAB (24 tablets) are required for a complete preparation for colonoscopy. Twelve (12) tablets are equivalent to one dose. Each SUTAB bottle contains a desiccant. Remove and discard the desiccant from both bottles the evening prior to the colonoscopy. Water must be consumed with each dose of SUTAB and additional water must be consumed after each dose. Complete all SUTAB tablets and required water at least 2 hours before colonoscopy.

WARNINGS AND PRECAUTIONS
Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Colonic mucosal ulcerations: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease. Suspected GI obstruction or perforation: Rule out the diagnosis before administration. Hypersensitivity reactions, including anaphylaxis: Inform patients to seek immediate medical care if symptoms occur. Risk of Gastrointestinal Complications with Ingestion of Desiccant: Postmarketing reports of ingestion of the desiccant along with SUTAB tablets has been reported and may be associated with risk of gastrointestinal complications and/or choking.

ADVERSE REACTIONS
Most common gastrointestinal adverse reactions are: nausea, abdominal distension, vomiting, and upper abdominal pain.

DRUG INTERACTIONS
Drugs that increase risk of fluid and electrolyte imbalance.

View the Full Prescribing Information and Medication Guide.

References: 1. IQVIA, National Prescription Audit Report. December 2023. 2. SUTAB [package insert]. Braintree, MA: Braintree Laboratories, Inc. 3. Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. 2021;116(2):319-328. doi: 10.14309/ajg.0000000000001020. 4. Rex DK, Johnson DA, Anderson JC, et al; American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104(3):739-750. 5. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017;112(7):1016-1030. doi:10.1038/ajg.2017.174. 6. Rex DK, Anderson JC, Butterfly LF, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2024;100(3):352-381. doi:10.1016/j.gie.2024.04.2905 7. Data on file. Braintree Laboratories, Inc. Braintree, MA. 8. SUFLAVE [package insert]. Braintree, MA: Braintree Laboratories, Inc. 9. SUPREP Bowel Prep Kit [package insert]. Braintree, MA: Braintree Laboratories, Inc. 10. Plenvu [package insert]. Bridgewater, NJ: Bausch Health LLC. 11. Clenpiq [package insert]. Parsippany, NJ: Ferring Pharmaceuticals, Inc. 12. Rex DK, Di Palma JA, Rodriguez R, et al. A randomized clinical study comparing reduced-volume oral sulfate solution with standard 4-liter sulfate-free electrolyte lavage solution as preparation for colonoscopy. Gastrointest Endosc. 2010;72(2):328-336. 13. Matro R, Daskalakis C, Negoianu D, et al. Randomised clinical trial: polyethylene glycol 3350 with sports drink vs polyethylene glycol with electrolyte solution as purgatives for colonoscopy—the incidence of hyponatraemia. Aliment Pharmacol Ther. 2014;40(6):610-619.

SUFLAVE IMPORTANT SAFETY INFORMATION

INDICATION

SUFLAVE^™ (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution) is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

DOSAGE AND ADMINISTRATION

A low residue breakfast may be consumed on the day before colonoscopy, followed by clear liquids up to 2 hours prior to colonoscopy. Administration of two doses of SUFLAVE are required for a complete preparation for colonoscopy. Each bottle must be reconstituted with water before ingestion. Each bottle and one flavor enhancing packet are equivalent to one dose. An additional 16 ounces of water must be consumed after each dose. Stop consumption of all fluids at least 2 hours before the colonoscopy.

CONTRAINDICATIONS

Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to any ingredient in SUFLAVE.

WARNINGS AND PRECAUTIONS

Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Colonic mucosal ulcerations: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration; Patients at risk for aspiration: Observe during administration; Hypersensitivity reactions, including anaphylaxis: Inform patients to seek immediate medical care if symptoms occur.

ADVERSE REACTIONS

Most common adverse reactions (≥2%) are: nausea, abdominal distension, vomiting, abdominal pain, and headache.

DRUG INTERACTIONS

Drugs that increase risk of fluid and electrolyte imbalance.

View the Full Prescribing Information and Medication Guide.

References: 1. Rex DK, Anderson JC, Butterfly LF, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2024;100(3):352-381. doi:10.1016/j.gie.2024.04.2905 2. SUTAB [package insert]. Braintree, MA: Braintree Laboratories, Inc. 3. Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. 2021;116(2):319-328. doi:10.14309/ajg.0000000000001020 4. SUFLAVE [package insert]. Braintree, MA: Braintree Laboratories, Inc. 5. Bhandari R, Goldstein M, Mishkin DS, et al. Comparison of a novel, flavor-optimized, polyethylene glycol and sulfate bowel preparation with oral sulfate solution in adults undergoing colonoscopy. J Clin Gastroenterol. 2023;57(9):920-927. doi:10.1097/MCG.0000000000001894